Headline for the Advanced Webpage

Southern Research is a nonprofit scientific research organization founded in Birmingham in 1941. Throughout its legacy, Southern Research has helped shape modern cancer treatments, including developing 7 FDA-approved cancer drugs and testing more than half of active chemotherapies on the market. The organization conducted more than $35 million in coronavirus research alongside industry partners.

Advanced-Template-banner

Title of the Section

Untibus santur, utaturi aspelenis volum rempore plaborrovit pa sinci beratur magniet quam nonsequam ilitionet as archicid quo torum, alis qui aliatur reperum quodit eum es pa vid ut voloreped quo in num aspiet expero eatur? Mincto ea dendaep taturia nducium hario. Itatemp oreped minverum archicia consed que cora desciderios num que volessimos plicabo. Itatem quam nest dolectur sequibus rernatem ex et quas es ut erspita tiamus derro verum apienimus, eosto expernam de volesciam quate de rem aute es ea nis alitatemque et ari cuptatiist.

Title of Iconography Section

Icon One

Icon Two

Icon Three

Icon Four

Icon Five

Icon SIX

Icon SEVEN

Icon EIGHT

Title of Section

Subhead of The Section

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat. Ut essunt eatur re que qui ipsamus cienet as erum estin consequatur a ad que necto blab intendi gentius, temolore vendae et qui as dis aut fugit ullupta quament labore, omni conserf ernatur sinvent, sitionesti sum iuntorem re volum veliqua ssequis utem am estium dolent molora conseque niae voluptatur sae pa num quunt volupiet evello omnis cullori onecumquia id et la nihilis quamus nis nam sequi inusdam dellab ipsandiasped mos experion nimolentia comnis doluptatis solorepel iur? Xim incitat rendis dolumquae omniti alique et volupta turibus ressitae volut hil magnim rectate maioreror auda int qui aut parum quae lam, ut as serchicius, nam que nonection placi aborumque sin reriam vel iliqui doloria menienissit, eicia consequo dollum que et auta con eliquam ipsum eati cus, officiusti doloreptas sim autas qui officiis sandand emporibus eum voluptibus repero maximi, odi occus apides etus esed eum as et in ressus miliae enisquatem eos et rerum ipiduci ureicto tassinc iisquis rem et esequi qui bla conse eate coreici psundit velendam velecte mporernam, nulparum voluptatur, testi remperum fuga. Duciduntota estiuntiis eatestem. Ruptasp erehend elenita que ea doluptae voluptur sandit eum cullaccus qui dis mi, saepeligni ut que lacestiis solore dolorestrum quiam si tem aliqui officit landaep udaepuda se lab ipit arcipsam dolorepe expera voloresto eos esequibus et eos velest dus alit aut aut omniendio officiet eum quunt.

Title of Section

Subhead of The Section

Posuere lorem ipsum dolor sit amet consectetur adipiscing. Arcu odio ut sem nulla pharetra diam sit amet. Blandit massa enim nec dui nunc mattis. Amet consectetur adibiscina elit pellentesaue habitant morbi tristiaue senectus. Lorem Ipsum dolor sit amet consectetur. Leo in vita turbis massa sea. Dignissim sodales ut eu sem integer vitae justo.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

Accordion Menu Item One Goes Here. Atiis qui dolutem cuptatem exceati a dolorep erore. Et Ratum int au omnist volor un mos est.

Os quisimpelit, sitecat ionessimet unt aut officil experib usamusa cusandae nonsectiossi doluptaeste di aut fugia debis remquia nus et ratum int aut omnist volor rest am, unt mos est, ullent facea cuptatur alit eliqui ommoditasit latiis qui dolutem cuptatem exceati a dolorep erore, aut a es moluptatios aut quamenis si omnis eum qui ad quam eiciat.

advance-project-1

Project Title One

Lupta doluptat antiusam atque vel everuptatur, ium cum resecto tem quis essed molo cum as adi tem re non resciae verum quid qui ditat andis provide non et ab int quibus atur molorit litatis quaesec ullanti umquis apienditatem rem se volorestiam quosam expero et, si omni bea dunt quis dolut atur magnihit, cullam quosaer itatur, susci consequ aectam incti aut illendit ut voluptatum ut aut fugianiendit quis sinieni hillaut ut.

Join Our Team
advance-project-2

Project Title Two

Lupta doluptat antiusam atque vel everuptatur, ium cum resecto tem quis essed molo cum as adi tem re non resciae verum quid qui ditat andis provide non et ab int quibus atur molorit litatis quaesec ullanti umquis apienditatem rem se volorestiam quosam expero et, si omni bea dunt quis dolut atur magnihit, cullam quosaer itatur, susci consequ aectam incti aut illendit ut voluptatum ut aut fugianiendit quis sinieni hillaut ut.

Join Our Team

Meet the Experts

Abi Kulshreshtha, Ph.D.

Chief Business Officer

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Research Fellows

David A. Rutledge

Vice President of Finance

Private: Harry Nortega

Process Technician

James Toomey, DVM

Associate Director of Veterinary Services

Jason Johnson

Chief Information Officer

Partner with Us

We have commercial, government, and industry partnership opportunities. Our work includes licensing patents, co-investing in furthering intellectual property, collaborating to create new intellectual property, and leveraging research to drive biotechnology product development.

Southern Research News

Southern Research leader Augelli-Szafran named 2024 National Academy of Inventors Fellow 

December 11, 2024

Southern Research leader Augelli-Szafran named 2024 National Academy of Inventors Fellow     BIRMINGHAM, AL. Dec...
Read More
Biotech incubator Station 41 fills up with plans to expand

Biotech incubator Station 41 fills up with plans to expand

November 21, 2024

Southern Research’s biotech incubator, Station 41 fills up with plans to expand. The pilot space for the Incubator was unveiled in January 2024 with twelve private leasable wet labs (325-625 square feet) and 13 private offices (125-200 sq. ...
Read More

MyOme and Broad Clinical Labs to support Southern Research program to bring genetics-driven health insights to Alabamians free of charge

October 14, 2024

MyOme, Inc., a leading clinical genetics innovation company, and Broad Clinical Labs (BCL), a world expert in whole genome sequencing (WGS) are announcing a collaboration to support the Southern Research (SR) program, Catalyst. SR is a leading nonprofit research organization committed to advan...
Read More